Osteoarthritis and Diabetes: Where Are We and Where Should We Go?

被引:12
|
作者
Alenazi, Aqeel M. [1 ]
Alhowimel, Ahmed S. [1 ]
Alshehri, Mohammed M. [2 ]
Alqahtani, Bader A. [1 ]
Alhwoaimel, Norah A. [1 ]
Segal, Neil A. [3 ]
Kluding, Patricia M. [4 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Dept Hlth & Rehabil Sci, Alkharj 11942, Saudi Arabia
[2] Jazan Univ, Dept Phys Therapy, Jazan 45142, Saudi Arabia
[3] Univ Kansas, Dept Phys Med & Rehabil, Med Ctr, Kansas City, KS 66160 USA
[4] Univ Kansas, Dept Phys Therapy & Rehabil Sci, Med Ctr, Kansas City, KS 66160 USA
关键词
osteoarthritis; diabetics; high blood glucose; pain intensity; symptoms; gait; pace; RADIOGRAPHIC KNEE OSTEOARTHRITIS; EARLY POSTOPERATIVE OUTCOMES; CLINICALLY DIAGNOSED KNEE; HAND OSTEOARTHRITIS; RISK-FACTORS; METABOLIC SYNDROME; GENERALIZED OSTEOARTHRITIS; UNITED-STATES; WALKING SPEED; ASSOCIATION;
D O I
10.3390/diagnostics13081386
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) and osteoarthritis (OA) are chronic noncommunicable diseases that affect millions of people worldwide. OA and DM are prevalent worldwide and associated with chronic pain and disability. Evidence suggests that DM and OA coexist within the same population. The coexistence of DM in patients with OA has been linked to the development and progression of the disease. Furthermore, DM is associated with a greater degree of osteoarthritic pain. Numerous risk factors are common to both DM and OA. Age, sex, race, and metabolic diseases (e.g., obesity, hypertension, and dyslipidemia) have been identified as risk factors. These risk factors (demographics and metabolic disorder) are associated with DM or OA. Other possible factors may include sleep disorders and depression. Medications for metabolic syndromes might be related to the incidence and progression of OA, with conflicting results. Given the growing body of evidence indicating a relationship between DM and OA, it is vital to analyze, interpret, and integrate these findings. Therefore, the purpose of this review was to evaluate the evidence on the prevalence, relationship, pain, and risk factors of both DM and OA. The research was limited to knee, hip, and hand OA.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Smart energy: where do we stand and where should we go?
    Kranz, Johann
    Kolbe, Lutz M.
    Koo, Chulmo
    Boudreau, Marie-Claude
    ELECTRONIC MARKETS, 2015, 25 (01) : 7 - 16
  • [32] The outcomes movement in orthopaedic surgery: Where we are and where we should go
    不详
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1999, 81A (05): : 732 - +
  • [33] The Future of IBD Therapy: Where Are We and Where Should We Go Next?
    Mao, Ren
    Hu, Pin-Jin
    DIGESTIVE DISEASES, 2016, 34 (1-2) : 175 - 179
  • [34] The Elderly Patient and the ICU: Where Are We Going, Where Should We Go?
    Riou, Bruno
    Boddaert, Jacques
    CRITICAL CARE MEDICINE, 2016, 44 (01) : 231 - +
  • [35] Smart energy: where do we stand and where should we go?
    Johann Kranz
    Lutz M. Kolbe
    Chulmo Koo
    Marie-Claude Boudreau
    Electronic Markets, 2015, 25 : 7 - 16
  • [36] Over-education and earnings: where are we, where should we go?
    Hartog, J
    ECONOMICS OF EDUCATION REVIEW, 2000, 19 (02) : 131 - 147
  • [38] Personalized medicine and healthcare: where are we now, where should we go?
    Laszlo, Gulacsi
    Szabolcs, Bekassy
    Nora, Bittner
    Judit, Feith Helga
    Andrea, Ficzere
    Lajos, Horvath
    Zsolt, Horvath
    Ico, Toth
    Zsombor, Zrubka
    Erika, Toth
    Gabor, Kovacs L.
    ORVOSI HETILAP, 2023, 164 (06) : 202 - 209
  • [39] CHEST PAIN OF ESOPHAGEAL ORIGIN - WHERE ARE WE, AND WHERE SHOULD WE GO
    BENJAMIN, SB
    CASTELL, DO
    ARCHIVES OF INTERNAL MEDICINE, 1983, 143 (04) : 772 - 776
  • [40] Pheochromocytoma - where are we? Where should we go? A medical and scientific odyssey
    Neumann, HPH
    Opocher, G
    Januszewicz, A
    Eng, C
    FAMILIAL CANCER, 2005, 4 (01) : 1 - 1